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Peroxisome proliferator-activated receptor gamma (PPAR-γ) belongs to the nuclear hormone receptor subfamily of transcription
factors. PPARs are expressed in key target tissues such as liver, fat, and muscle and thus they play a major role in the regulation
of energy balance. Because of PPAR-γ’s role in energy balance, signals originating from the gut (e.g., GIP), fat (e.g., leptin), mus-
cle (e.g., myostatin), or bone (e.g., GILZ) can in turn modulate PPAR expression and/or function. Of the two PPAR-γ isoforms,
PPAR-γ2isthekeyregulatorofadipogenesisandalsoplaysaroleinbonedevelopment.Activationofthisreceptorfavorsadipocyte
diﬀerentiation of mesenchymal stem cells, while inhibition of PPAR-γ2 expression shifts the commitment towards the osteoblas-
togenic pathway. Clinically, activation of this receptor by antidiabetic agents of the thiazolidinedione class results in lower bone
mass and increased fracture rates. We propose that inhibition of PPAR-γ2 expression in mesenchymal stem cells by use of some of
the hormones/factors mentioned above may be a useful therapeutic strategy to favor bone formation.
Copyright © 2007 Xingming Shi et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The peroxisome proliferator-activated receptor gamma
(PPAR-γ) family of transcription factors belongs to the nu-
clear hormone receptor subfamily of transcription factors
that can bind to speciﬁc DNA response elements in the reg-
ulatory regions of target genes. Other isotypes of this family
include PPAR alpha (PPAR-α) and PPAR beta/delta (PPAR-
β/-δ). Each of these isotypes is encoded by a diﬀerent gene
and has diﬀerent functions and diﬀerent tissue distribution
[1]. Many excellent reviews have been published recently on
the regulation of nuclear receptors belonging to the PPAR
family [2–12] and the reader is referred to one of these re-
views for an overview on these nuclear receptors.
The current review more narrowly focuses on PPAR-γ2,
i t sr o l ei nb o n ef o r m a t i o n ,a n di t sr e g u l a t i o nb yt h ee n e r g y
state. Bone, like other tissues in the body, requires a posi-
tive energy balance to grow. However, even with a positive
energy balance, bone progenitor cells can diﬀerentiate into
osteoblast, adipocyte, or muscle cells. PPAR-γ2i sak e yr e g -
ulator of this diﬀerentiation step in bone marrow progenitor
cells. Tissues in the body important in regulating this energy
balance include skeletal muscle, adipocytes, and liver (see
Figure 1). The crosstalk between these target tissues occurs
viabothcentralnervoussystem(CNS)outputandperipheral
hormones from enteric, pancreatic, or adipocytic sources.
Studies from our laboratories have focused on enteric hor-
mones like glucose-dependent insulinotropic peptide (GIP),
adipocytic hormones like leptin, and skeletal muscle-derived
factors such as myostatin in addition to transcriptional reg-
ulators such as the glucocorticoid-induced leucine zipper
(GILZ) in the regulation of osteoblast/adipocyte diﬀeren-
tiation from bone marrow progenitor cells. The impact of
changes in the organism’s energy balance on mesenchymal
stem cell diﬀerentiation will be discussed in more detail be-
low.
2. PEROXISOME PROLIFERATOR-ACTIVATED
RECEPTOR
PPAR-γ is highly expressed in adipose tissue although it
is also expressed in other tissues including skeletal muscle,2 PPAR Research
intestine, endothelium, prostate, and white blood cells [13].
The gene for PPAR-γ is localized on chromosome 3 [13]
and there are two protein products, PPAR-γ1 and PPAR-γ2,
which are isoforms transcribed from the same gene with dif-
ferent promoter usage [14, 15]. PPAR-γ2 is predominantly
expressed in adipose tissue, while PPAR-γ1i sm o r ew i d e l y
expressed [10]. Of these two isoforms, PPAR-γ2i sak e yr e g -
ulator of adipogenesis [16–18] and is expressed at an early
stage of the adipogenesis program [19]. PPAR-γ2c a na c t i -
vate a battery of genes necessary for lipid metabolism, in-
cluding lipoprotein lipase (LPL) [20], phosphoenolpyruvate
carboxykinase (PEPCK) [21], fatty acid-binding and trans-
port proteins [22], and stearoyl-CoA desaturase-1 (SCD-1)
[23].FunctionalPPARresponseelements(PPREs)havebeen
identiﬁedinthepromoterregionsofthesegenes.Inaddition,
activation of PPAR-γ2 by its ligand [24, 25] induces cell cycle
withdrawal and terminal adipocyte diﬀerentiation in a vari-
ety of mesenchymal cell lines [26–29]. Thus, the pivotal reg-
ulatory role that PPAR-γ2 plays in adipocyte diﬀerentiation
is recognized by its early and tissue-speciﬁc expression [19]
and its ability to direct ﬁbroblasts and myoblasts to diﬀeren-
tiate into adipocytes when it is ectopically expressed in these
cells [28, 30].
Most importantly, a recent in vivo study has demon-
strated that PPAR-γ insuﬃciency in mice (PPAR-γ+/−)r e -
sults in a dramatic decrease (by 50%) in adipogenesis with a
concomitant increase in osteogenesis through osteoblast for-
mation from marrow progenitors [31]. This study suggests
the possibility of interrupting the PPAR-γ pathway as a novel
treatment of osteoporosis.
3. MESENCHYMAL STEM CELLS
Mesenchymal stem cells (MSCs) are multipotent cells that,
under appropriate culture conditions, can diﬀerentiate into
multiple cell lineages, including osteoblasts, myoblasts, and
adipocytes [32–35]. Considerable evidence has shown that
the commitment between osteoblast and adipocyte lineages
from MSCs is reciprocal, that is, when the adipogenic path-
way is blocked, MSCs enter the osteogenic pathway, and vice
versa [36–40].Increasedmarrowadipogenesisnegativelyim-
pacts bone formation because mesenchymal precursor cells
are directed towards the adipocyte lineage rather than to the
osteoblast lineage [41, 42]. Marrow adipocytes can also in-
hibit osteoblast proliferation in vitro, and adipocytes secrete
factors such as IL-6 and TNFα [43] that stimulate the dif-
ferentiation of the bone-resorbing cells, osteoclasts [44]. The
negative impact of marrow adipogenesis on bone health is
further indicated by the fact that bone formation rate is in-
versely correlated with adipocyte number in bone biopsies of
adult men and women [45], and women with osteoporosis
have higher number of marrow adipocytes than those with
healthy bone [46].
Clinically, much recent attention has focused on drugs
belonging to the thiazolidinedione class. These medications
(e.g., rosiglitazone and pioglitazone) are PPAR agonists used
to treat patients with diabetes mellitus, and have recently
been associated with impaired bone quality, increased mar-
row fat, and increased fracture rates [47, 48].
Understanding the regulators of MSC diﬀerentiation be-
tween fat and bone has gained increasing importance with
increasing human longevity since, as humans age, the num-
berofadipocytesincreasesandthenumberofosteoblastsde-
creases resulting in weakened bone, age-related osteoporosis,
and fragility fractures. Because of the importance of PPAR-
γ2i nM S Cd i ﬀerentiation into adipocytes or osteoblasts, we
will brieﬂy discuss some of the regulators of the PPAR-γ2r e -
ceptor.
4. REGULATION OF THE PPAR-γ RECEPTOR
Regulation of the PPAR-γ receptor activity can occur via (1)
changes in receptor expression levels or (2) changes in tran-
scriptional activity (see Figure 2).
A number of transcription factors can either posi-
tively or negatively modulate PPAR-γ receptor expression
in adipocytes [49]. Major transcription factors activat-
ing PPAR-γ receptor expression include CCAAT/enhancer-
binding protein (C/EBP) family of transcription factors and
these have been reviewed extensively elsewhere [2, 50]. Al-
though GATA-1, -2, Wnt (Wnt10b), epidermal growth fac-
tor(EGF),platelet-derivedgrowthfactor(PDGF),andtrans-
forming growth factor beta (TGF-β) play important roles in
PPAR-γ regulation, they will not be discussed in this review.
PPAR-γ receptor transcriptional activity is regulated by
two distinct processes: repression of receptor activity by
phosphorylation (by kinases such as mitogen-activated pro-
tein, MAP kinases, which activate Jun N-terminal kinase, or
JNK, and extracellular signal-regulated kinase 2, or ERK-2)
and increased receptor activity by ubiquitination. Agonists
for the nuclear PPAR-γ receptor include protein kinase A,
natural fatty acids, eicosanoids, and oxidized lipoproteins.
LesswellstudiedarenegativeregulatorsofthenuclearPPAR-
γ receptor. Activators of MAPK and thus inhibitors of PPAR-
γ receptor transcriptional activity include growth factors like
epidermal growth factor (EGF), platelet-derived growth fac-
tor (PDGF), transforming growth factor β’s (TGF-β’s) 1 and
2, and GILZ. Both insulin and glucocorticoid induce the ex-
pressionofC/EBP-β and-δ,whichinturninducetheexpres-
sion of PPAR-γ and C/EBP-α and initiate the adipogenesis
program.
5. NUTRITION-RELATED HORMONES
Enteric hormones represent the mechanism by which in-
gested nutrients are distributed to the various tissues in the
body so as to maximize their utilization. These hormones
play a key role in regulating the energy balance, in part
through modulation of PPAR expression. In fact, elevation
of incretin hormones, through use of inhibitors of the en-
zyme that breaks them down (DPP-IV inhibitors), has been
shown to increase PPAR expression in the kidney [51].
Nutritional hormones are also known to be important in
bone turnover as evidenced by the fact that as soon as a meal
is ingested, bone breakdown is suppressed. Many nutrition-
related hormones have been shown to have eﬀects on bone
turnover through in vitro or in vivo studies including (a)
Intestinal Hormones such as (1) GIP, (2) Ghrelin, and (3)Xingming Shi et al. 3
Glucagon-like peptide- (GLP-2); (b) Pancreatic Hormones
such as (1) Insulin, (2) Amylin, (3) Adrenomedullin, and (4)
Preptin; (c) Adipocyte-secreted Hormones such as (1) Leptin,
(2) Adiponectin, and (3) Resistin, as recently reviewed by
Clowes et al. [52] and Reid et al. [53]. For purposes of this
review, we will focus more extensively on GIP and leptin but
discuss these other hormones brieﬂy below.
5.1. Intestinalhormones
Ghrelin is a 28-amino acid peptide expressed predominantly
in the gastric epithelium and small intestine, though it is also
expressed to a lower extent in the brain, pancreatic islets,
adrenal cortex, kidney, and bone [54]. Ghrelin’s physiologic
function is to stimulate growth hormone secretion, and sys-
temic elevations of ghrelin stimulate food intake and weight
gain. Ghrelin’s systemic eﬀects on energy metabolism appear
to oppose those of leptin. Ghrelin receptors are expressed
on osteoblasts and ghrelin stimulates osteoblastic prolifera-
tion and diﬀerentiation [55, 56]. In addition, intraperitoneal
infusion of ghrelin for four weeks resulted in signiﬁcant in-
creases in bone mineral density in Sprague-Dawley rats [55].
In humans, the data supporting a role for ghrelin in bone
turnover are less clear. Ghrelin levels have a signiﬁcant nega-
tive correlation with markers of bone breakdown at baseline,
althoughnotwithbonemineraldensity,andghrelininfusion
has no acute eﬀect on these markers [57, 58].
GLP-2isa33-aminoacidpeptideexpressedmainlyinthe
L cells of the small intestine. GLP-2 is secreted in response
to nutrient ingestion and its physiologic function appears
to be to regulate intestinal motility and stimulate intestinal
cell growth; it is also antiapoptotic [59]. GLP-2 receptors are
expressed in osteoclasts and the administration of GLP-2 to
human subjects inhibits bone resorption and increases bone
mass [60–62].
5.2. Pancreatichormones
Insulin has long been considered the main anabolic hor-
mone,stimulatingboneformationinvitro.However,invivo,
although insulin infusion is known to decrease markers of
bone breakdown, this eﬀect is only about 30% of the decline
in resorption markers that occurs postprandially. In fact, it
hasbeensuggestedthatthiseﬀectisduetohypoglycemiaand
the attendant impairment in skeletal cellular activity rather
than to a direct antiresorptive eﬀect [63].
Amylin is a 37-amino acid hormone cosecreted from
the pancreatic β cells with insulin in response to a meal.
Amylin lowers serum calcium, inhibits bone resorption, and
increases bone mass in mice [64–66].
Adrenomedullin is a 52-amino acid peptide related to
amylin; it is expressed in the adrenal medulla, vasculature
brain, kidney, and bone [67]. Adrenomedullin stimulates os-
teoblastic proliferation and injection of adrenomedullin to
mice increases bone formation and strength without a major
eﬀect on bone breakdown [68, 69].
Preptin is a 37-amino acid peptide cosecreted from the
pancreatic islet with amylin and insulin. Preptin stimulated
osteoblastic proliferation, and the daily injection of this pep-
tide for ﬁve days over the calvaria resulted in increased bone
area and mineralized surface through increased bone for-
mation rather than through inhibition of bone breakdown
[70].
5.3. Adipocytichormones
Adiponectin is a 247-amino acid protein strongly expressed
in mature adipocytes (particularly in subcutaneous versus
visceral adipocytes) and the levels correlate with the de-
gree of diﬀerentiation [71]. Thus, PPAR-γ agonists (e.g.,
thiazolidinediones) are potent stimulators of adiponectin
expression. Adiponectin suppresses both cell proliferation
and release of other inﬂammatory cytokines [71]. Both the
adiponectin protein and its receptor are expressed in os-
teoblasts and osteoclasts, and its eﬀects on bone turnover
are complex [72, 73]. In humans, adiponectin levels have
been shown to be negatively correlated with bone mineral
density [74], particularly in postmenopausal female patients
[75].
Resistin is a 137-amino acid protein secreted from
adipocytes [76]. In addition to adipocytes, resistin is also
expressed in pancreas, brain, and bone marrow. In the
adipocyte, resistin expression is regulated by PPAR-γ with
PPAR-γ agonists such as rosiglitazone resulting in an inhi-
bition of resistin expression [77]. Resistin secretion results
in insulin resistance. In the bone, resistin is expressed in os-
teoblast, osteoclast, and mesenchymal stem cells [76]a n dr e -
sistin levels are negatively correlated with bone mineral den-
sity [78].
5.4. Glucose-dependentinsulinotropicpeptide
There are two major intestinal hormones that potentiate
glucose-induced insulin secretion (incretin eﬀect), that is,
GIP and glucagon-like peptide-1 (GLP-1). GLP-1 receptors
are not present in bone cells [79]. GIP was ﬁrst identiﬁed in
the 1970’s as a hormone secreted by cells in the enteric en-
docrine system (K cells) in the proximal small intestine. Be-
cause this 42-amino acid peptide was found to inhibit gastric
acid secretion, it was initially named gastric inhibitory pep-
tide (GIP) [80]. Subsequent studies demonstrated that GIP
eﬀects on inhibiting gastric acid secretion did not occur at
physiological concentrations, in contrast to GIP eﬀects on
potentiating glucose-induced insulin secretion. Thus GIP’s
namewaschangedtoglucose-dependentinsulinotropic pep-
tide. Our data and resulting publications demonstrate that
GIP also serves as an important anabolic signal for bone,
stimulating bone formation and inhibiting bone breakdown.
To summarize our GIP data in vitro, (1) GIP receptors are
present in both osteoblasts and osteoclasts [81, 82]; (2) in
osteoblasts, GIP increases collagen type I synthesis and in-
creases alkaline phosphatase activity [81]; (3) in osteoblasts,
GIP stimulates proliferation [81]; and (4) in osteoclasts, GIP
inhibits PTH-induced long bone resorption and decreases
osteoclastic resorption pit depth [82]. In in vivo studies, (5)
GIP receptor knockout mice have a lower bone mass, de-
creased serum markers of bone formation, and increased
markers of bone breakdown [83], consistent with data4 PPAR Research
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Figure 1: Nutrition and tissue-generated hormonal signals modulate mesenchymal stem cell diﬀerentiation. Hormonal signals generated upon
nutrient ingestion impact the organism’s energy balance, thus favoring anabolic versus catabolic activities. In turn, hormonal signals gener-
ated by target tissues such as muscle, bone, and fat modulate MSC diﬀerentiation into adipocytes or osteoblasts.
published by others, [84] and (6) GIP-overexpressing trans-
genic mice have increased bone mass, lower serum markers
of bone breakdown, and increased markers of bone forma-
tion [85].
The GIP receptor knockout mouse was developed by
Miyawaki and colleagues [86], and it is an interesting ani-
mal model linking nutritional hormones and bone forma-
tion. These knockout mice are not diﬀerent from control
mice in their weight, basal insulin, glucose levels, or in their
insulin response to an intraperitoneal glucose tolerance test.
However, blood glucose levels, in response to an oral glu-
cose tolerance test or a high-fat diet, are higher in the knock-
out mice compared to controls, and the higher blood glu-
cose levels in the knockout mice are associated with lower
insulin levels. A subsequent report, also by Miyawaki et al.
[87], demonstrates that although normal mice fed a high-fat
diet gained weight, GIP receptor knockout mice were pro-
tected from the large weight gain associated with this diet.
Interestingly, GIPR knockout mice fed a high-fat diet had
lower leptin levels than control mice fed a high-fat diet (2-
fold increase from basal in GIPR
−/− versus 4-fold increase
in WT). Furthermore, if GIPR
−/− mice are crossed with the
obesemousemodelLep ob/Lepob togeneratedoublehomozy-
gous mice, these double homozygous mice are partially pro-
tected from the weight gain seen in the Lepob/Lepob mice
(GIPR
−/−/Lepob/Lepob had a 23% lower body weight). The
authors conclude that under normal conditions an excessive
amount of fat in the diet leads to GIP hypersecretion; this in
turn leads to more adiposity, resulting in obesity and insulin
resistance.
In our studies, we found that if the GIP receptor is down-
regulated, bone mass decreases and bone marrow adipocyte
content increases [85]. These ﬁndings would suggest the
possibility of direct GIP eﬀects on MSCs. In fact, we have
d e m o n s t r a t e dt h a tG I Pr e c e p t o r sa r ep r e s e n to nM S C sa n d
that stimulation of these cells with GIP promotes osteoblas-
tic diﬀerentiation [88].
6. LEPTIN
The cytokine-like hormone leptin is recognized as a power-
ful regulator of appetite and energy balance [89]. Adipocytes
are the primary source of leptin in the body and as such
leptin plays an important role as a signal of energy sta-
tus to the brain [90]. Leptin produced by peripheral body
fat enters the circulation and crosses the blood-brain bar-
rier to reach leptin receptors located in the hypothalamus.
Leptin binding to the long form of the leptin receptor in-
duces the expression of anorexigenic neuropeptides such as
cocaine-amphetamine-related transcript (CART) and alpha-
melanocyte-stimulating hormone (α-MSH), and suppresses
the activity of orexigenic genes such as neuropeptide Y
(NPY) and agouti-related peptide (AgRP), that are involved
in regulating food intake [91].Leptin also regulates sym-
pathetic outﬂows and functions as a beta-adrenergic ago-
nist [92], and intrahypothalamic injections of leptin induce
apoptosis of adipocytes in both peripheral fat and bone mar-
row [93]. Adipocytes express beta-adrenergic receptors, par-
ticularly beta 3 [94], and activation of these receptors can in-
duce apoptosis through activation of a tyrosine kinase path-
way [95].
Leptin also appears to regulate adipocyte populations in
bone marrow directly, in addition to the central eﬀects of
leptin on adipocyte apoptosis. Leptin-deﬁcient ob/ob mice
show a signiﬁcant increase in bone marrow adipocytes com-
pared to lean mice [96], and peripheral leptin injections de-
crease the population of bone marrow adipocytes in ob/ob
mice and increase bone formation [97]. As discussed above,
the loss of bone marrow adipocytes with peripheral leptin
treatment may be a centrally mediated eﬀect, but the in-
creased osteogenic diﬀerentiation and increased endocorti-
cal bone formation are more consistent with a direct eﬀect of
leptin on osteogenic diﬀerentiation [89]. Bone marrow stro-
mal cells (BMSCs) express leptin receptors, and leptin bind-
ing increases the expression of osteogenic genes and directsXingming Shi et al. 5
Insulin
fatty acids
TZDs
TGF-β
Wnt 10b
Adipocytes
Osteoblast
Nucleus
Nucleus
Nucleus
+
+
GATA 2,3
TCF4
PPAR-γ2
PPAR-γ2
PPAR-γ2
Mesenchymal
stem cell
C/EBP-β and -δ
ADD-1/SREBP-1
+
−
1. Regulation of PPAR-γ2 receptor expression
(a)
Insulin
fatty acids
glucocorticoids
Adipocytes
Osteoblast
Nucleus
+
+
MAPK
JNK
ERK 2
GILZ
PPAR-γ2
Mesenchymal
stem cell
Ubiquination
PKA
Transcriptional
activity
Transcriptional
activity
2. Regulation of PPAR-γ2 receptor transcriptional activity
(b)
Figure 2: PPAR-γ2 action is modulated by either changes in receptor expression or transcriptional activity. (a) Natural (insulin, long-chain fatty
acids,oreicosanoids)orsyntheticligands(TZDs)tothePPAR-γ2receptorcaneitherincreaseordecreasereceptorexpressionresultinginin-
creased adipocytic or increased osteoblastic diﬀerentiation, respectively. (b) It is also possible to stimulate or inhibit PPAR-γ2 transcriptional
activity resulting in either increased adipocytic or osteoblastic diﬀerentiation, respectively.
BMSCs to the osteogenic rather than the adipogenic path-
way[98].InstudiesbyThomasetal.[98],leptindidnotalter
PPAR-γ or Cbfa-1 expression despite increasing osteogenesis
and decreasing adipogenesis presumably by acting at a later
stage in osteoblast diﬀerentiation. Bone marrow adipocytes
secrete leptin themselves [99], raising the possibility that lep-
tin may play a role in autocrine or paracrine signaling within
the bone marrow microenvironment. We have found that
age-associated bone loss in mice is associated with decreased
serum leptin [100], and as noted earlier, aging is associated
with bone loss and an increased accumulation of bone mar-
row adipocytes. These data suggest that leptin treatment, in
conditions of increased leptin sensitivity (see below), may
have signiﬁcant potential for increasing bone formation and
decreasing marrow adipogenesis with aging.
7. MYOSTATIN
Myostatin was initially identiﬁed as a factor regulating myo-
genic diﬀerentiation because its expression was localized to
developing skeletal muscle, and because myostatin loss-of-
function was observed to have dramatic eﬀects on muscle
mass in mice. It was, however, also noted that mice lack-
ing myostatin showed decreased body fat [101, 102], and6 PPAR Research
myostatin deﬁciency decreased adiposity in leptin-deﬁcient
ob/ob mice [102]. This was thought to be an indirect eﬀect
oftheincreasedmusclemassonmetabolism.Sincethattime,
we and others have found that myostatin deﬁciency inhibits
adipogenesis in vivo, even when mice are fed a high-fat diet
[103]. Transgenic overexpression of myostatin propeptide,
whichinhibitsmyostatinsignaling,alsoinhibitsbodyfatgain
with a high-fat diet [104]. Similar alterations in myostatin
signaling are associated with changes in body fat among hu-
mans. A child with a naturally occurring mutation in the
myostatin gene was shown to have increased muscle mass as
wellasdecreasedsubcutaneousfat[105].Weightlossinmor-
bidlyobesesubjectswasassociatedwithsigniﬁcantdownreg-
ulation of myostatin mRNA in muscle biopsies, suggesting
a role for myostatin in energy partitioning between protein
and fat [106].
Although the in vivo data consistently show that myo-
statin has an adipogenic eﬀect, and that myostatin deﬁ-
ciency has an anti-adipogenic eﬀect, the in vitro data are less
clear. Myostatin has been observed to promote adipogenesis
in multipotential mouse C3H 10T (1/2) mesenchymal stem
cells [107], but myostatin can also inhibit adipocyte diﬀer-
entiation in 3T3-L1 mouse preadipocytes [108] and inhibit
BMP-7-mediated adipogenesis by binding to the same re-
ceptor as BMP-7, the activin IIB (ActRIIB) receptor [109].
These data suggest that the decreased fat mass of myostatin-
deﬁcient animals is simply an indirect eﬀect of increased
muscle mass since other mouse models showing increased
muscle mass, such as transgenic mice overexpressing Akt
[110]a n dS k i[ 111], also show decreased fat mass. How-
ever, we have recently identiﬁed expression of the myostatin
receptor in bone marrow-derived mesenchymal stem cells
(BMSCs), and found that BMSCs from myostatin-deﬁcient
mice demonstrate increased osteogenic diﬀerentiation and
decreased adipogenic diﬀerentiation [112]. There are not
many studies examining the eﬀect of myostatin on PPAR-γ
expression. A study by Artaza et al. [107] demonstrated that
myostatin increased expression of C/EBP alpha and adipo-
genesis in mesenchymal stem cells, suggesting a myostatin
eﬀect on PPAR-γ, although they did not actually examine
PPAR-γ expression. These data are consistent with previ-
ous reports showing increased bone mineral density in the
bones of myostatin-deﬁcient animals [113–115]. Further-
more, these data from bone marrow cells provide further
evidence that myostatin is an adipogenic factor, as well as
one that suppresses myogenesis and perhaps osteogenesis. In
contrast, a study by Hirai et al. [116] found that myostatin
inhibited PPAR-γ and C/EBP alpha expression in bovine
preadipocytes. Thus, myostatin eﬀects on PPAR-γ may be
cell-type-dependent.
8. GLUCOCORTICOID-INDUCED LEUCINE ZIPPER
GILZ, which is also induced by estrogen and sonic hedge-
hog (Shh), is a new member of the leucine zipper protein
[117, 118] and belongs to the TGF-β-stimulated clone-22
(TSC-22) family of transcription factors [119, 120]. Mem-
bers of this familyof proteins containthree distinct domains:
an N-terminus TSC box, a middle leucine zipper domain,
and a C-terminus polyproline-rich domain. GILZ was origi-
nally identiﬁed from dexamethasone-treated murine thymo-
cytes [118]. Recent studies have shown that GILZ is also in-
duced in many tissues (including lung, liver, brain, and kid-
ney) and by the other glucocorticoids that are prescribed
frequently in clinic such as methylprednisolone, ﬂuticasone,
and hydrocortisone, as well as anti-inﬂammatory cytokine
interleukin-10 (IL-10) in human and murine macrophages
[121–123]. Studies carried out in vitro have shown that over-
expression of GILZ protected T cells from apoptosis induced
by anti-CD3 antibody, but not other apoptosis-inducing
agents such as dexamethasone, various doses of ultravio-
let irradiation, starvation, or triggering induced by cross-
linked anti-Fas monoclonal antibody [118]. However, T-cell-
speciﬁc transgenic overexpression of GILZ resulted in thy-
mocyte apoptosis ex vivo possibly through downregulation
of Bcl-xL [124]. GILZ also inhibits interleukin-2 (IL2)/IL-2
receptor expression (63). This antiapoptotic function is me-
diated through direct protein-protein interactions between
GILZ and NF-kB, and between GILZ and AP-1 (63–67). The
directinteractionsofGILZwithNF-kB,andGILZwithAP-1,
block DNA binding and, therefore, the transcriptional activ-
ities of NF-kB and AP-1.
Studies by Shi et al. [125] found that GILZ is rapidly in-
duced by dexamethasone in MSCs and a variety of cell lines,
including osteoblasts (2T3), preadipocytes (3T3-L1), and a
mesenchymal cell line (C3H10T1/2). It is interesting to note
that the induction of GILZ in MSCs and C3H10T1/2 cells
seems transient. GILZ can bind speciﬁcally toa 40-bp DNA
fragment containing a unique tandemly repeated C/EBP-
binding element present in the promoter of the PPAR-γ2
gene. Because glucocorticoids induce adipocyte diﬀerentia-
tion, and GILZ is induced by glucocorticoids and binds to
adipogenic PPAR-γ2promoter,itwashypothesized thatcon-
stitutive expression of GILZ would activate PPAR-γ2e x p r e s -
sion and enhance adipogenesis. Contrary to expectations,
overexpressionofGILZinhibitedPPAR-γ2transcriptionand
blocked adipocyte diﬀerentiation of C3H10T1/2 mesenchy-
mal cells and 3T3-L1 preadipocytes. These results demon-
strated that GILZ functions as a transcriptional repressor of
PPAR-γ2. Studies by Zhang et al. (unpublished data) show
that overexpression of GILZ in mouse bone marrow MSCs
can enhance MSC osteoblast diﬀerentiation. These data sug-
gest that, by modulating PPAR-γ expression, GILZ may serve
as an important regulator of the MSC lineage commitment
between osteoblast and adipocyte. This role of GILZ may
have potential clinic importance since as humans age, the
numberofadipocytesincreaseandthenumberofosteoblasts
decrease resulting in weakened bone and age-related osteo-
porosis and fragility fractures. All these may have direct con-
nection to the increased PPAR-γ expression and activity in
aging bone marrow as it is known that aging activates mar-
row adipogenesis and fat secretes large amounts of cytokines
that will, in turn, inhibit osteogenesis as mentioned earlier.
As previously mentioned, the transcriptional activity of
PPAR-γ is regulated by phosphorylation (by kinases such as
the mitogen-activated protein kinase (MAPK), which acti-
vate Jun N-terminal kinase, or JNK, and extracellular signal-
regulated kinase 2, or ERK 2), and GILZ can directly interactXingming Shi et al. 7
with Raf1, one of the MAPK members, resulting in the inhi-
bition of Raf-1 phosphorylation and, subsequently, the sup-
pression of both MEK/ERK-1/2 phosphorylation and AP-1-
dependent transcription [119].
It has been a long standing paradox that glucocorticoids,
while required for osteoblast diﬀerentiation of primary bone
marrow stromal cells in vitro [126–128] ,i n d u c eb o n el o s si n
vivo. Since GILZ is induced by glucocorticoids and enhances
MSC osteogenesis, we speculate that GILZ is the actual me-
diator of glucocorticoid action in this process. The possible
pathways in which GILZ may convey therapeutic eﬀects of
glucocorticoids have been reviewed by Clark and Lasa [129].
Undernormalconditions,GClevelsﬂuctuateinresponse
to environmental stressors (ﬂight/ﬁght, abrupt temperature
changes, etc.). When the GC level is increased, GILZ is in-
ducedandpreventsadipogenic diﬀerentiation. Underpatho-
physiological or pharmacological conditions, however, GC is
elevatedforaprolongedperiodoftimeandthenegativefeed-
back network is overwhelmed, resulting in harmful GC side
eﬀects, such as bone loss.
9. GIP, LEPTIN, MYOSTATIN, AND GILZ AS
THERAPEUTIC TARGETS
Adequate nutrition and a positive energy balance are clearly
importantforbonegrowth.Areductionincaloricintakewill
retard growth plate expansion [130]. In addition, if the re-
duced caloric intake is accompanied by a reduced calcium
intake, a shift in the balance between bone formation and
resorption occurs, such that bone mass decreases over time
[131]. In contrast, an increase in intake and gain in weight
are associated with an increase in bone mass. Upon nutri-
ent delivery to the intestine, there is a rapid rise in a num-
ber of enteric hormones that serve to inform the target tis-
sues that nutrients are available for anabolic activity. One of
theseenterichormones,GLP-2,hasalreadybeenusedtopre-
vent bone loss in postmenopausal patients [62], although no
data are available on marrow adiposity. Our data would sug-
gest that GIP is another enteric hormone that can increase
bone formation by promoting MSC diﬀerentiation into os-
teoblasts.
One of the challenges in using recombinant leptin ther-
apy to either reduce body weight, suppress appetite, or stim-
ulate bone formation is that most individuals are relatively
resistant to exogenous leptin treatment due to relatively
high levels of endogenous leptin [89, 96]. However, leptin
may have signiﬁcant eﬀects on bone formation and appetite
in conditions where leptin sensitivity is increased with en-
ergy deprivation. For example, leptin treatment has been
observed to increase serum IGF-1 and serum osteocalcin
in women with exercise-induced hypothalamic amenorrhea
[132]. Anorexia nervosa is associated with markedly reduced
leptin levels and osteoporosis [133–135]e v e ni fl e s ss e v e r e ,
voluntary weight loss is associated with increased rates of
bonelossinadults[136,137].Leptintreatmentmayhavepo-
tential to reverse bone loss with weight loss, as well as main-
tenance of reduced weight following weight loss [138].
Treatment of normal rodents and dystrophin-deﬁcient
mdx mice with factors that block myostatin signaling, such
as a soluble myostatin receptor, a propeptide, or follis-
tatin, showed signiﬁcant increases in muscle mass and im-
proved muscle regeneration [139, 140]. The myostatin an-
tibody MYO 029 is currently in Phase II clinical trials for
treatment of Duchenne muscular dystrophy. To date, myo-
statin inhibitors have only been tested for their ability to im-
prove muscle regeneration in cases of muscular dystrophy
and acute injury, and their potential for inhibiting body fat
gain and stimulating bone formation remains relatively un-
explored. We expect that myostatin inhibitors have signiﬁ-
cant potential as novel therapies for decreasing adiposity and
also improving bone formation and bone strength. More-
over, as noted earlier in this paper, glucorticoids play a ma-
jor role in stimulating bone marrow adipogenesis, and the
myostatin promoter is known to have a glucocorticoid re-
sponse element [141]. Myostatin deﬁciency inhibits muscle
atrophy with glucocorticoid treatment [142], and myostatin
inhibitors may be useful for attenuating muscle atrophy and
bone loss with prolonged use of glucocorticoids.
Bone cells are derived from marrow MSCs, and the best
way to increase the number of bone-forming cells is to mod-
ulate diﬀerentiation pathways so that more MSCs are di-
rected to the osteoblastogenesis pathway. The PPAR-γ path-
way not only regulates adipocyte diﬀerentiation, but also in-
hibits osteoblast diﬀerentiation from mesenchymal progeni-
tors[31],suggestingthepossibilityofinterruptingthePPAR-
γ pathway as a novel treatment of osteoporosis. GILZ, in-
duced transiently by GC, is a sequence-speciﬁc transcrip-
tional repressor of PPAR-γ [143]. No transcriptional repres-
sors that can bind speciﬁcally to the promoter of PPAR-γ
have been reported so far. Thus, GILZ may be a novel thera-
peutictargetfordrugdevelopmentforavarietyofconditions
characterized by an altered adipocyte/osteoblast balance.
In summary, current therapeutic targets for prevention
and treatment of osteoporosis involve anabolic agents stimu-
lating osteoblastic activity or antiresorptive agents targeting
the osteoclasts. Our data would suggest that modulating the
MSC diﬀerentiation pathway, particularly via inhibition of
the PPAR-γ2 receptor, thus favoring osteoblastic instead of
adipocytic diﬀerentiation, might be an attractive therapeutic
target for prevention and treatment of osteoporosis.
ACKNOWLEDGMENTS
This work was supported in part by funding from the Na-
tional Institutes of Health (R01DK058680, C. M. Isales; R01
AR049717, M. Hamrick) and the American Heart Associa-
tion (X. Shi).
REFERENCES
[1] C. Blanquart, O. Fruchart, B. Fruchart, B. Steals, and C.
Glineur, “Peroxisome proliferator-activated receptors: regu-
lationoftranscriptionalactivitiesandrolesininﬂammation,”
The Journal of Steroid Biochemistry and Molecular Biology,
vol. 85, no. 2–5, pp. 267–273, 2003.
[2] S. R. Farmer, “Regulation of PPARγ activity during adipoge-
nesis,” International Journal of Obesity, vol. 29, suppl. 1, pp.
13–16, 2005.8 PPAR Research
[3] S. L. Gray, E. Dalla Nora, and A. J. Vidal-Puig, “Mouse
models of PPAR-γ deﬁciency: dissecting PPAR-γ’s role in
metabolic homoeostasis,” Biochemical Society Transactions,
vol. 33, no. 5, pp. 1053–1058, 2005.
[4] M. Gurnel, “Peroxisome proliferator-activated receptor
gamma and the regulation of adipocyte function,” Best Prac-
tice & Research. Clinical Endocrinology & Metabolism, vol. 19,
no. 4, pp. 501–523, 2005.
[5] B. P. Kota, T. H. Huang, and B. D. Roufogalis, “An overview
on biological mechanisms of PPARs,” Pharmacological Re-
search, vol. 51, no. 2, pp. 58–94, 2005.
[6] M.A.Lazar,“PPARgamma,10yearslater,”Biochimie,vol.87,
no. 1, pp. 9–13, 2005.
[7] M. Lehrke and M. A. Lazar, “The many faces of
PPARgamma,” Cell, vol. 123, no. 6, pp. 993–999, 2005.
[8] S. Miard and L. Fajas, “Atypical transcriptional regulators
and cofactors of PPAR-γ,” International Journal of Obesity,
vol. 29, suppl. 1, pp. 10–12, 2005.
[9] L. A. Moraes, L. Piqueras, and D. Bishop-Bailey, “Peroxisome
proliferator-activated receptors and inﬂammation,” Pharma-
cology & Therapeutics, vol. 110, no. 3, pp. 371–385, 2006.
[10] R.K.Semple,V .K.Chatt erjee,andS.O ’Rahilly ,“PP AR -γ and
human metabolic disease,” The Journal of Clinical Investiga-
tion, vol. 116, no. 3, pp. 581–589, 2006.
[11] B.StaelsandJ.C.Fruchart,“Therapeuticrolesofperoxisome
proliferator-activated receptor agonists,” Diabetes, vol. 54,
no. 8, pp. 2460–2470, 2005.
[12] N.S.Tan,L.Michalik,B.Desvergne,andW.Wahli,“Multiple
expression control mechanisms of peroxisome proliferator-
activated receptors and their target genes,” The Journal of
Steroid Biochemistry and Molecular Biology, vol. 93, no. 2–5,
pp. 99–105, 2005.
[13] S. Theocharis, A. Margeli, P. Vielh, and G. Kouraklis, “Perox-
isome proliferator-activated receptor-gamma ligands as cell-
cycle modulators,” Cancer Treatment Reviews, vol. 30, no. 6,
pp. 545–554, 2004.
[14] R. Mukherjee, L. Jow, G. E. Croston, and J. R. Pater-
niti Jr., “Identiﬁcation, characterization, and tissue distri-
bution of human peroxisome proliferator-activated receptor
(PPAR) isoforms PPAR-γ2v e r s u sP P A R - γ1 and activation
with retinoid X receptor agonists and antagonists,” The Jour-
nal of Biological Chemistry, vol. 272, no. 12, pp. 8071–8076,
1997.
[15] Y. Zhu, C. Qi, J. R. Korenberg, et al., “Structural organi-
zation of mouse peroxisome proliferator-activated receptor-
γ (mPPAR-γ) gene: alternative promoter use and diﬀerent
splicing yield two mPPAR-γ isoforms,” Proceedings of the Na-
tional Academy of Sciences of the United States of America,
vol. 92, no. 17, pp. 7921–7925, 1995.
[16] Y. Barak, M. C. Nelson, E. S. Ong, et al., “PPAR γ is re-
quired for placental, cardiac, and adipose tissue develop-
ment,” Molecular Cell, vol. 4, no. 4, pp. 585–595, 1999.
[17] E. D. Rosen, P. Sarraf, A. E. Troy, et al., “PPAR gamma is re-
quired for the diﬀerentiation of adipose tissue in vivo and in
vitro,” Molecular Cell, vol. 4, no. 4, pp. 611–617, 1999.
[18] P. Tontonoz, E. Hu, R. A. Graves, A. L. Budavari, and B. M.
Spiegelman, “mPPAR gamma 2: tissue-speciﬁc regulator of
an adipocyte enhancer,” Genes & Development, vol. 8, no. 10,
pp. 1224–1234, 1994.
[ 1 9 ]A .C h a w l a ,E .J .S c h w a r z ,D .D .D i m a c u l a n g a n ,a n dM .A .
Lazar, “Peroxisome proliferator-activated receptor (PPAR)
gamma: adipose-predominant expression and induction
early in adipocyte diﬀerentiation,” Endocrinology, vol. 135,
no. 2, pp. 798–800, 1994.
[20] K. Schoonjans, J. Peinado-Onsurbe, A. M. Lefebvre, et al.,
“PPARalpha and PPARgamma activators direct a distinct
tissue-speciﬁc transcriptional response via a PPRE in the
lipoprotein lipase gene,” The EMBO Journal, vol. 15, pp.
5336–5348, 1996.
[ 2 1 ] P .T o n t o n o z ,E .H u ,J .D e v i n e ,E .G .B e a l e ,a n dB .M .S p i e g e l -
man, “PPAR gamma 2 regulates adipose expression of the
phosphoenolpyruvate carboxykinase gene,” Molecular and
Cellular Biology, vol. 15, no. 1, pp. 351–357, 1995.
[22] B. I. Frohnert, T. Y. Hui, and D. A. Bernlohr, “Identiﬁcation
of a functional peroxisome proliferator-responsive element
in the murine fatty acid transport protein gene,” The Journal
of Biological Chemistry, vol. 274, no. 7, pp. 3970–3977, 1999.
[23] C. W. Miller and J. M. Ntambi, “Peroxisome proliferators in-
ducemouseliverstearoyl-CoAdesaturase1geneexpression,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 93, no. 18, pp. 9443–9448, 1996.
[24] B.M.Forman,P .T ontonoz,J .Chen,R.P .Brun,B.M.Spiegel-
man, and R. M. Evans, “15-Deoxy-Δ
12, 14-prostaglandin j2
is a ligand for the adipocyte determination factor PPAR-γ,”
Cell, vol. 83, no. 5, pp. 803–812, 1995.
[25] S. A. Kliewer, J. M. Lenhard, T. M. Willson, I. Patel, D. Mor-
ris, and J. M. Lehmann, “A prostaglandin j2 metabolite binds
peroxisome proliferator-activated receptor-γ and promotes
adipocyte diﬀerentiation,” Cell, vol. 83, no. 5, pp. 813–819,
1995.
[ 2 6 ]S .A l t i o k ,M .X u ,a n dB .M .S p i e g e l m a n ,“ P P A R g a m m ai n -
duces cell cycle withdrawal: inhibition of E2F/DP DNA-
binding activity via down-regulation of PP2A,” Genes & De-
velopment, vol. 11, no. 15, pp. 1987–1998, 1997.
[27] J. M. Gimble, C. E. Robinson, X. Wu, et al., “Peroxisome
proliferator-activated receptor-gamma activation by thiazo-
lidinediones induces adipogenesis in bone marrow stromal
cells,” Molecular Pharmacology, vol. 50, no. 5, pp. 1087–1094,
1996.
[ 2 8 ]E .H u ,P .T o n t o n o z ,a n dP .M .S p i e g e l m a n ,“ T r a n s d i ﬀeren-
tiation of myoblasts by the adipogenic transcription factors
PPAR-γ and C/EPBα,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 92, pp. 9856–
9860, 1995.
[29] J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O.
Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic
thiazolidinedione is a high aﬃnity ligand for peroxisome
proliferator-activated receptor gamma (PPAR gamma),” The
Journal of Biological Chemistry, vol. 270, no. 50, pp. 12953–
12956, 1995.
[30] P. Tontonoz, E. Hu, and P. M. Spiegelman, “Stimulation
of adipogenesis in ﬁbroblasts by PPAR gamma 2, a lipid-
activated transcription factor,” Cell, vol. 79, no. 7, pp. 1147–
1156, 1994.
[31] T. Akune, S. Ohba, S. Kamekura, et al., “PPAR-γ insuﬃ-
ciency enhances osteogenesis through osteoblast formation
from bone marrow progenitors,” The Journal of Clinical In-
vestigation, vol. 113, no. 6, pp. 846–855, 2004.
[32] S. P. Bruder, N. Jaiswal, and S. E. Haynesworth, “Growth ki-
netics, self-renewal, and the osteogenic potential of puriﬁed
human mesenchymal stem cells during extensive subcultiva-
tion and following cryopreservation,” Journal of Cellular Bio-
chemistry, vol. 64, no. 2, pp. 278–294, 1997.
[33] J. J. Minguell, A. Erices, and P. Conget, “Mesenchymal stem
cells,” Experimental Biology and Medicine, vol. 226, pp. 507–
520, 2001.Xingming Shi et al. 9
[34] M.F.Pittenger,A.M.Mackay,S.C.Beck,etal.,“Multilineage
potential of adult human mesenchymal stem cells,” Science,
vol. 284, no. 5411, pp. 143–147, 1999.
[35] D. J. Prockop, “Marrow stromal cells as stem cells for non-
hematopoietic tissues,” Science, vol. 276, no. 5309, pp. 71–74,
1997.
[36] S. Ahdjoudj, F. Lasmoles, B. O. Oyajobi, A. Lomri, P.
Delannoy, and P. J. Marie, “Reciprocal control of os-
teoblast/chondroblast and osteoblast/adipocyte diﬀerenti-
ation of multipotential clonal human marrow stromal
F/STRO-1(+) cells,” Journal of Cellular Biochemistry, vol. 81,
no. 1, pp. 23–38, 2001.
[37] T. Akune, S. Ohba, S. Kamekura, et al., “PPARγ insuﬃciency
enhances osteogenesis through osteoblast formation from
bone marrow progenitors,” The Journal of Clinical Investiga-
tion, vol. 113, no. 6, pp. 846–855, 2004.
[38] J.N.Beresford,J.H.Bennett,C.Devlin,P.S.Leboy,andM.E.
Owen, “Evidence for an inverse relationship between the dif-
ferentiation of adipocytic and osteogenic cells in rat marrow
stromal cell cultures,” Journal of Cell Science, vol. 83, no. 102,
pt. 2, pp. 341–351, 1992.
[39] F. Gori, T. Thomas, K. C. Hicok, T. C. Spelsberg, and B. L.
Riggs, “Diﬀerentiation of human marrow stromal precursor
cells: bone morphogenetic protein-2 increases OSF2/CBFA1,
enhancesosteoblastcommitment,andinhibitslateadipocyte
maturation,” Journal of Bone and Mineral Research, vol. 14,
pp. 1522–1535, 1999.
[40] R. K. Jaiswal, N. Jaiswal, S. P. Bruder, G. Mbalaviele, D. R.
Marshak, and M. F. Pittenger, “Adult human mesenchymal
stem cell diﬀerentiation to the osteogenic or adipogenic lin-
eage is regulated by mitogen-activated protein kinase,” The
Journal of Biological Chemistry, vol. 275, no. 13, pp. 9645–
9652, 2000.
[41] B.Lecka-Czernik,E.J .M oerman,D .F .Grant,J .M.Lehmann,
S. C. Manolagas, and R. L. Jilka, “Divergent eﬀects of se-
lective peroxisome proliferator-activated receptor-γ2 ligands
on adipocyte versus osteoblast diﬀerentiation,” Endocrinol-
ogy, vol. 143, no. 6, pp. 2376–2384, 2002.
[42] M. E. Nuttall and J. M. Gimble, “Is there a therapeutic op-
portunity to either prevent or treat osteopenic disorders by
inhibiting marrow adipogenesis?” Bone,v o l .2 7 ,n o .2 ,p p .
177–184, 2000.
[43] A. C. Maurin, P. M. Chavassieux, L. Frappart, P. D. Del-
mas, C. M. Serre, and P. J. Meunier, “Inﬂuence of mature
adipocytes on osteoblast proliferation in human primary co-
cultures,” Bone, vol. 26, no. 5, pp. 485–489, 2000.
[44] S. K. Fried, D. A. Bunkin, and A. S. Greenberg, “Omental
and subcutaneous adipose tissues of obese subjects release
interleukin-6: depot diﬀerence and regulation by glucocorti-
coid,” The Journal of Clinical Endocrinology and Metabolism,
vol. 83, no. 3, pp. 847–850, 1998.
[45] S. Verma, J. H. Rajaratnam, J. Denton, J. A. Hoyland, and R.
J. Byers, “Adipocytic proportion of bone marrow is inversely
relatedtoboneformationinosteoporosis,” JournalofClinical
Pathology, vol. 55, no. 9, pp. 693–698, 2002.
[46] J. Justesen, K. Stenderup, and M. S. Kassem, “Mesenchymal
stem cells. Potential use in cell and gene therapy of bone
loss caused by aging and osteoporosis,” Ugeskrift for Laeger,
vol. 163, no. 40, pp. 5491–5495, 2001.
[47] A. Grey, M. Bolland, G. Gamble, et al., “The peroxisome
proliferator-activated receptor-γ agonist rosiglitazone de-
creases bone formation and bone mineral density in healthy
postmenopausalwomen:arandomized,controlledtrial,”The
JournalofClinicalEndocrinology&Metabolism,vol.92,no.4,
pp. 1305–1310, 2007.
[48] A. V. Schwartz, “Diabetes, TZDs, and Bone,” AR e v i e wo ft h e
Clinical Evidence, vol. 2006, Article ID 24502, 2006.
[49] S. Miard and L. Fajas, “Atypical transcriptional regulators
and cofactors of PPARγ,” International Journal of Obesity,
vol. 29, suppl. 1, pp. 10–12, 2005.
[50] E. D. Rosen and L. Fajas, “Atypical transcriptional regulators
and cofactors of PPARγ,” Prostaglandins, Leukotrienes, and
Essential Fatty Acids, vol. 73, no. 1, pp. 31–34, 2005.
[51] C.W .P ark,H.W .K im,S.H.K o ,etal.,“L o ng-t e rmtr eatme nt
of glucagon-like peptide-1 analog exendin-4 ameliorates di-
abetic nephropathy through improving metabolic anomalies
in db/db mice,” Journal of the American Society of Nephrology,
vol. 18, no. 4, pp. 1227–1238, 2007.
[52] J.A.Clowes,S.Khosla,R.Eastell,etal.,“Potentialroleofpan-
creatic and enteric hormones in regulating bone turnover,”
JournalofBoneandMineralResearch,vol.20,no.9,pp.1497–
1506, 2005.
[53] I. R. Reid, J Cornish, and P. A. Baldock, “Nutrition-related
peptides and bone homeostasis,” Journal of Bone and Mineral
Research, vol. 21, no. 4, pp. 495–500, 2006.
[54] N. A. Tritos and E. G. Kokkotou, “The physiology and poten-
tialclinicalapplicationsofghrelin,anovelpeptidehormone,”
Mayo Clinic Proceedings, vol. 81, no. 5, pp. 653–660, 2006.
[55] N. Fukushima, R. Hanada, H. Teranishi, et al., “Ghrelin di-
rectlyregulatesboneFormation,”JournalofBoneandMineral
Research, vol. 20, no. 5, pp. 790–798, 2005.
[56] S. W. Kim, S. J. Her, S. J. Park, et al., “Ghrelin stimulates
proliferation and diﬀerentiation and inhibits apoptosis in os-
teoblastic MC3T3-E1 cells,” Bone, vol. 37, no. 3, pp. 359–369,
2005.
[57] M. S. Huda, B. H. Durham, S. P. Wong, et al., “Lack of an
acuteeﬀectofghrelinonmarkersofboneturnoverinhealthy
controls and post-gastrectomy subjects,” Bone,v o l .4 1 ,n o .3 ,
pp. 406–413, 2007.
[58] L. A. Weiss, C. Langenberg, E. Barrett-Connor, et al., “Ghre-
linandbone:isthereanassociationinolderadults?:theRan-
cho Bernardo study,” Journal of Bone and Mineral Research,
vol. 21, no. 5, pp. 752–757, 2006.
[59] L. L. Baggio and D. J. Drucker, “Clinical endocrinology
and metabolism. Glucagon-like peptide-1 and glucagon-like
peptide-2,” Best Practice & Research. Clinical Endocrinology &
Metabolism, vol. 18, no. 4, pp. 531–554, 2004.
[60] D. B. Henriksen, P. Alexandersen, N. H. Bjarnason, et al.,
“Roleofgastrointestinalhormonesinpostprandialreduction
of bone resorption,” Journal of Bone and Mineral Research,
vol. 18, no. 12, pp. 2180–2189, 2003.
[61] D. B. Henriksen, P. Alexandersen, I. Byrjalsen, et al., “Reduc-
tion of nocturnal rise in bone resorption by subcutaneous
GLP-2,” Bone, vol. 34, no. 1, pp. 140–147, 2004.
[62] D. B. Henriksen, P. Alexandersen, B. Hartmann, et al., “Dis-
association of bone resorption and formation by GLP-2A 14-
day study in healthy postmenopausal women,” Bone, vol. 40,
no. 3, pp. 723–729, 2007.
[63] N. H. Bjarnason, E. E. Henriksen, P. Alexandersen, S. Christ-
gau, D. B. Henriksen, and C. Christiansen, “Mechanism of
circadian variation in bone resorption,” Bone, vol. 30, no. 1,
pp. 307–313, 2002.
[ 6 4 ]J .C o r n i s h ,K .E .C a l l o n ,A .R .K i n g ,G .J .S .C o o p e r ,a n dI .
R. Reid, “Systemic administration of amylin increases bone
mass, linear growth, and adiposity in adult male mice,” The
American Journal of Physiology Links, vol. 275, no. 4, pp.
E694–E699, 1998.10 PPAR Research
[65] J. Cornish, K. E. Gallon, C. Q. Lin, et al., “Dissociation of the
eﬀectsofamylinonosteoblastproliferationandboneresorp-
tion,” The American Journal of Physiology, vol. 274, no. 5, pp.
E827–E833, 1998.
[66] M. Zaidi, V. S. Shankar, C. L.-H. Huang, M. Paizanas, and S.
R. Bloom, “Amylin in bone conservation: current evidence
and hypothetical considerations,” Trends in Endocrinology
and Metabolism, vol. 4, no. 8, pp. 255–259, 1993.
[67] J. Cornish and I. R. Reid, “Eﬀects of amylin and
adrenomedullin on the skeleton,” Journal of Musculoskeletal
& Neuronal Interactions, vol. 2, no. 1, pp. 15–24, 2001.
[68] J. Bronsky, R. Prusa, and J. Nevoral, “The role of amylin and
related peptides in osteoporosis,” Clinica Chimica Acta; Inter-
national Journal of Clinical Chemistry, vol. 373, no. 1–2, pp.
9–16, 2006.
[69] J.Cornish,K.E.Callon,U.Bava,etal.,“Systemicadministra-
tion of adrenomedullin(27-52) increases bone volume and
strength in male mice,” Journal of Endocrinologyl, vol. 170,
no. 1, pp. 251–257, 2001.
[70] J.Cornish,K.E.Callon,U.Bava,etal.,“Preptin,anotherpep-
tide product of the pancreatic β-cell, is osteogenic in vitro
a n di nv i v o , ”American Journal of Physiology. Endocrinology
and Metabolism, vol. 292, no. 1, pp. E117–E122, 2007.
[71] A. Koerner and J. Kratzsch, “Kiess W. Adipocytokines:
leptin—the classical, resistin—the controversical,
adiponectin—the promising, and more to come,” Best
Practice & Research. Clinical Endocrinology & Metabolism,
vol. 19, no. 4, pp. 525–546, 2005.
[72] X. H. Luo, L. J. Guo, H. Xie, et al., “Adiponectin stimulates
RANKL and inhibits OPG expression in human osteoblasts
through the MAPK signaling pathway,” Journal of Bone and
Mineral Research, vol. 21, no. 10, pp. 1648–1656, 2006.
[73] Y. Shinoda, M. Yamaguchi, N. Ogata, et al., “Regulation of
bone formation by adiponectin through autocrine/paracrine
and endocrine pathways,” Journal of Cellular Biochemistry,
vol. 99, no. 1, pp. 196–208, 2006.
[74] L. Lenchik, T. C. Register, F. C. Hsu, et al., “Adiponectin as a
novel determinant of bone mineral density and visceral fat,”
Bone, vol. 33, no. 4, pp. 646–651, 2003.
[ 7 5 ]J .B .R i c h a r d s ,A .M .V a l d e s ,K .B u r l i n g ,U .C .P e r k s ,T .D .
Spector, et al., “Serum adiponectin and bone mineral density
in women,” Journal of Clinical Endocrinology & Metabolism,
vol. 92, no. 4, pp. 1517–1523, 2007.
[76] L. Thommesen, A. K. Stunes, M. Monjo, et al., “Expression
and regulation of resistin in osteoblasts and osteoclasts indi-
cate a role in bone metabolism,” Journal of Cellular Biochem-
istry, vol. 99, no. 3, pp. 824–834, 2006.
[77] L. Patel, A. C. Buckels, I. J. Kinghorn, et al., “Resistin is ex-
pressed in human macrophages and directly regulated by
PPAR gamma activators,” Biochemical and Biophysical Re-
search Communications, vol. 300, no. 2, pp. 472–476, 2003.
[ 7 8 ]K .W .O h ,W .Y .L e e ,E .J .R h e e ,e ta l . ,“ T h er e l a t i o n s h i p
between serum resistin, leptin, adiponectin, ghrelin levels
and bone mineral density in middle-aged men,” Clinical En-
docrinology, vol. 63, no. 2, pp. 131–138, 2005.
[ 7 9 ]R .J .B o l l a g ,Q .Z h o n g ,K .H .D i n g ,e ta l . ,“ G l u c o s e -
dependent insulinotropic peptide is an integrative hormone
with osteotropic eﬀects,” Molecular and Cellular Endocrinol-
ogy, vol. 177, no. 1–2, pp. 35–41, 2001.
[80] J. C. Brown, V. Mutt, and R. A. Pederson, “Further puriﬁca-
tion of a polypeptide demonstrating enterogastrone activity,”
Journal of Physiology, vol. 209, no. 1, pp. 57–64, 1970.
[81] R. J. Bollag, Q. Zhong, P. Phillips, et al., “Osteoblast-derived
cells express functional glucose-dependent insulinotropic
peptide receptors,” Endocrinology, vol. 141, no. 3, pp. 1228–
1235, 2000.
[82] Q. Zhong, T. Itokawa, S. Sridhar, et al., “Eﬀects of
glucose-dependent insulinotropic peptide on osteoclast
function,” American Journal of Physiology—Endocrinology
and Metabolism, vol. 292, no. 2, pp. E543–E548, 2007.
[83] D. Xie, H. Cheng, M. Hamrick, et al., “Glucose-dependent
insulinotropic polypeptide receptor knockout mice have al-
tered bone turnover,” Bone, vol. 37, no. 6, pp. 759–769, 2005.
[84] K. Tsukiyama, Y. Yamada, C. Yamada, et al., “Gastric in-
hibitorypolypeptideasanendogenousfactorpromotingnew
bone formation after food ingestion,” Molecular Endocrinol-
ogy, vol. 20, no. 7, pp. 1644–1651, 2006.
[85] D.Xie,Q.Zhong,K.-H.Ding,etal.,“Glucose-DependentIn-
sulinotropic Peptide-Overexpressing Transgenic Mice Have
Increased Bone Mass,” Bone, vol. 40, pp. 1352–1360, 2007.
[86] K. Miyawaki, Y. Yamada, H. Yano, et al., “Glucose intolerance
causedbyadefectintheentero-insularaxis:astudyingastric
inhibitory polypeptide receptor knockout mice,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 96, no. 26, pp. 14843–14847, 1999.
[87] K. Miyawaki, Y. Yamada, N. Ban, et al., “Inhibition of gas-
tric inhibitory polypeptide signaling prevents obesity,” Na-
ture Medicine, vol. 8, pp. 738–742, 2002.
[88] X. Shi, M. Hamrick, B. Kang, et al., The Impact of Aging on
Stem Cell Diﬀerentiation Induced by Nutrition-Related Hor-
mones,InternationalFederationofAdiposeTherapeuticsand
Science, Baton Rouge, La, USA, 2006.
[89] M. W. Hamrick, “Invited perspective: leptin and bone—a
consensus emerging?” Bonekey Osteovision, vol. 4, pp. 99–
107, 2007.
[90] R. L. Leshan, M. Bj¨ ornholm, H. M¨ unzberg, and M. G. My-
ers Jr., “Leptin receptor signaling and action in the central
nervous system,” Obesity (Silver Spring), vol. 14, suppl. 5, pp.
208–212, 2006.
[91] B. M. Spiegelman and J. S. Flier, “Obesity and the regulation
of energy balance,” Cell, vol. 104, no. 4, pp. 531–543, 2001.
[92] S. Collins, C. M. Kuhn, A. E. Petro, A. G. Swick, B. A.
Chrunyk, and R. S. Surwit, “Role of leptin in fat regulation,”
Nature, vol. 380, no. 6576, p. 677, 1996.
[93] M. Hamrick, M. Della Fera, Y.-H. Choi, D. Hartzell, C. Pen-
nington,andC.Baile,“Injectionsofleptinintoratventrome-
dialhypothalamusincreaseadipocyteapoptosisinperipheral
fat and in bone marrow,” Cell and Tissue Research, vol. 327,
no. 1, pp. 133–141, 2007.
[94] S. Collins and R. S. Surwit, “The β-adrenergic receptors and
thecontrolofadiposetissuemetabolismandthermogenesis,”
Recent Progress in Hormone Research, vol. 56, pp. 309–328,
2001.
[95] Y. C. Ma and X. Y. Huang, “Novel signaling pathway
through the β-adrenergic receptor,” Trends in Cardiovascular
Medicine, vol. 12, no. 1, pp. 46–49, 2002.
[96] M. W. Hamrick, C. Pennington, D. Newton, D. Xie, and C.
Isales,“Leptindeﬁciencyproducescontrastingphenotypesin
bones of the limb and spine,” Bone, vol. 34, no. 3, pp. 376–
383, 2004.
[97] M.W.Hamrick,M.A.Della-Fera,Y.H.Choi,C.Pennington,
D. Hartzell, and C. A. Baile, “Leptin treatment induces loss
of bone marrow adipocytes and increases bone formation in
leptin-deﬁcient ob/ob mice,” Journal of Bone and Mineral Re-
search, vol. 20, no. 6, pp. 994–1001, 2005.
[ 9 8 ]T .T h o m a s ,F .G o r i ,S .K h o s l a ,M .D .J e n s e n ,B .B u r g u e r a ,
and B. L. Riggs, “Leptin acts on human marrow stromal
cells to enhance diﬀerentiation to osteoblasts and to inhibitXingming Shi et al. 11
diﬀerentiation to adipocytes,” Endocrinology, vol. 140, no. 4,
pp. 1630–1638, 1999.
[99] P. Laharrague, D. Larrouy, A. M. Fontanilles, et al., “High ex-
pression of leptin by human bone marrow adipocytes in pri-
mary culture,” FASEB Journal, vol. 12, no. 9, pp. 747–752,
1998.
[100] M. W. Hamrick, K. H. Ding, C. Pennington, et al., “Age-
related loss of muscle mass and bone strength in mice is as-
sociated with a decline in physical activity and serum leptin,”
Bone, vol. 39, no. 4, pp. 845–853, 2006.
[101] J. Lin, H. B. Arnold, M. A. Della-Fera, M. J. Azain, D. L.
Hartzell, and C. A. Baile, “Myostatin knockout in mice in-
creases myogenesis and decreases adipogenesis,” Biochemical
and Biophysical Research Communications, vol. 291, no. 3, pp.
701–706, 2002.
[102] A.C.McPherronandS.J.Lee,“Suppressionofbodyfataccu-
mulationinmyostatin-deﬁcientmice,”TheJournalofClinical
Investigation, vol. 109, pp. 595–601, 2002.
[103] M.W.Hamrick,C.Pennington,C.N.Webb,andC.M.Isales,
“Resistance to body fat gain in double-muscled mice fed a
high-fat diet,” International Journal of Obesity,v o l .3 0 ,n o .5 ,
pp. 868–870, 2006.
[104] B. Zhao, R. J. Wall, and J. Yang, “Transgenic expression of
myostatin propeptide prevents diet-induced obesity and in-
sulin resistance,” Biochemical and Biophysical Research Com-
munications, vol. 337, no. 1, pp. 248–255, 2005.
[105] M. Schuelke, K. R. Wagner, L. E. Stolz, et al., “Myostatin mu-
tation associated with gross muscle hypertrophy in a child,”
The New England Journal of Medicine, vol. 350, no. 26, pp.
2682–2688, 2004.
[106] G. Milan, E. Dalla Nora, C. Pilon, et al., “Changes in muscle
myostatin expression in obese subjects after weight loss,” The
JournalofClinicalEndocrinology&Metabolism,vol.89,no.6,
pp. 2724–2727, 2004.
[107] J. N. Artaza, S. Bhasin, T. R. Magee, et al., “Myostatin inhibits
myogenesis and promotes adipogenesis in C3H 10T(1/2)
mesenchymal multipotent cells,” Endocrinology, vol. 146,
no. 8, pp. 3547–3557, 2005.
[108] H. S. Kim, L. Liang, R. G. Dean, D. B. Hausman, D. L.
Hartzell, and C. A. Baile, “Inhibition of preadipocyte diﬀer-
entiation by myostatin treatment in 3T3-L1 cultures,” Bio-
chemical and Biophysical Research Communications, vol. 281,
no. 4, pp. 902–906, 2001.
[109] A. Rebbapragada, H. Benchabane, J. L. Wrana, A. J. Celeste,
and L. Attisano, “Myostatin signals through a transforming
growth factor β-like signaling pathway to block adipogene-
sis,” Molecular and Cellular Biology, vol. 23, no. 20, pp. 7230–
7242, 2003.
[110] K. M. Lai, M. Gonzalez, W. T. Poueymirou, et al., “Condi-
tional activation of akt in adult skeletal muscle induces rapid
hypertrophy,” Molecular and Cellular Biology, vol. 24, no. 21,
pp. 9295–9304, 2004.
[111] P. Sutrave, A. M. Kelly, and S. H. Hughes, “ski can cause se-
lectivegrowthofskeletalmuscleintransgenicmice,”Genes &
Development, vol. 4, no. 9, pp. 1462–1472, 1990.
[112] M. W. Hamrick, X. Shi, W. Zhang, et al., “Loss of myostatin
(GDF8) function increases osteogenic diﬀerentiation of bone
marrow-derived mesenchymal stem cells but the osteogenic
eﬀect is ablated with unloading,” Bone,v o l .4 0 ,n o .6 ,p p .
1544–1553, 2007.
[113] M. Hamrick, “Increased bone mineral density in the femora
of GDF8 knockout mice,” The Anatomical Record Part A:
Discoveries in Molecular, Cellular, and Evolutionary Biology,
vol. 272A, no. 1, pp. 388–391, 2003.
[114] M. W. Hamrick, C. Pennington, and C. D. Byron, “Bone ar-
chitecture and disc degeneration in the lumbar spine of mice
lacking GDF-8 (myostatin),” Journal of Orthopaedic Research,
vol. 21, no. 6, pp. 1025–1032, 2003.
[115] E. K. Nicholson, S. R. Stock, M. W. Hamrick, and M. J.
Ravosa, “Biomineralization and adaptive plasticity of the
temporomandibular joint in myostatin knockout mice,”
Archives of Oral Biology, vol. 51, no. 1, pp. 37–49, 2006.
[116] S. Hirai, H. Matsumoto, N. Hino, H. Kawachi, T. Matsui,
and H. Yano, “Myostatin inhibits diﬀerentiation of bovine
preadipocyte,” Domestic Animal Endocrinology, vol. 32, no. 1,
pp. 1–14, 2007.
[117] L.Cannarile,O.Zollo,F.D’Adamio,etal.,“Cloning,chromo-
somal assignment and tissue distribution of human GILZ, a
glucocorticoid hormone-induced gene,” Cell Death and Dif-
ferentiation, vol. 8, no. 2, pp. 201–203, 2001.
[118] F. D’Adamio, O. Zollo, R. Moraca, et al., “A new
dexamethasone-induced gene of the leucine zipper family
protectsTlymphocytesfromTCR/CD3-activatedcelldeath,”
Immunity, vol. 7, no. 6, pp. 803–812, 1997.
[119] E. Ayroldi, O. Zollo, A. Macchiarulo, B. Di Marco, C.
Marchetti, and C. Riccardi, “Glucocorticoid-induced leucine
zipper inhibits the Raf-extracellular signal-regulated kinase
pathwaybybindingtoRaf-1,”MolecularandCellularBiology,
vol. 22, no. 22, pp. 7929–7941, 2002.
[120] M. Shibanuma, T. Kuroki, and K. Nose, “Isolation of a gene
encoding a putative leucine zipper structure that is induced
by transforming growth factor β 1 and other growth fac-
tors,” The Journal of Biological Chemistry, vol. 267, no. 15, pp.
10219–10224, 1992.
[121] D. Berrebi, S. Bruscoli, N. Cohen, et al., “Synthe-
sis of glucocorticoid-induced leucine zipper (GILZ) by
macrophages: an anti-inﬂammatory and immunosuppres-
sive mechanism shared by glucocorticoids and IL-10,” Blood,
vol. 101, no. 2, pp. 729–738, 2003.
[122] S. Bruscoli, R. Di Virgilio, V. Donato, et al., “Genomic and
non-genomic eﬀects of diﬀerent glucocorticoids on mouse
thymocyte apoptosis,” European Journal of Pharmacology,
vol. 529, no. 1–3, pp. 63–70, 2006.
[123] P. Smit, H. Russcher, F. H. de Jong, A. O. Brinkmann,
S. W. Lamberts, and J. W. Koper, “Diﬀerential regulation
of synthetic glucocorticoids on gene expression levels of
glucocorticoid-induced leucine zipper and interleukin-2,”
JournalofClinicalEndocrinology&Metabolism,vol.90,no.5,
pp. 2994–3000, 2005.
[124] D. V. Delﬁno, M. Agostini, S. Spinicelli, P. Vito, and C. Ric-
cardi, “Decrease of Bcl-xL and augmentation of thymocyte
apoptosis in GILZ overexpressing transgenic mice,” Blood,
vol. 104, no. 13, pp. 4134–4141, 2004.
[125] X. Shi, W. Shi, Q. Li, et al., “A glucocorticoid-induced
leucine-zipper protein, GILZ, inhibits adipogenesis of mes-
enchymal cells,” EMBO Reports, vol. 4, no. 4, pp. 374–380,
2003.
[126] J. N. Beresford, C. J. Joyner, C. Devlin, and J. T. Triﬃtt, “The
eﬀects of dexamethasone and 1,25-dihydroxyvitamin D3 on
osteogenic diﬀerentiation of human marrow stromal cells in
vitro,” Archives of Oral Biology, vol. 39, no. 11, pp. 941–947,
1994.
[127] S. L. Cheng, J. W. Yang, L. Rifas, S. F. Zhang, and L. V. Avi-
oli, “Diﬀerentiation of human bone marrow osteogenic stro-
mal cells in vitro: induction of the osteoblast phenotype by
dexamethasone,” Endocrinology, vol. 134, no. 1, pp. 277–286,
1994.12 PPAR Research
[128] P.S.Leboy,J.N.Beresford,C.Devlin,andM.E.Owen,“Dex-
amethasone induction of osteoblast mRNAs in rat marrow
stromal cell cultures,” Journal of Cellular Physiology, vol. 146,
no. 3, pp. 370–378, 1991.
[129] A. R. Clark and M. Lasa, “Crosstalk between glucocorticoids
and mitogen-activated protein kinase signalling pathways,”
Current Opinion in Pharmacology, vol. 3, no. 4, pp. 404–411,
2003.
[130] C. Heinrichs, M. Colli, J. A. Yanovski, et al., “Eﬀects of fast-
ing on the growth plate: systemic and local mechanisms,” En-
docrinology, vol. 138, no. 12, pp. 5359–5365, 1997.
[131] A. F. Stewart and A. E. Broadus, “Mineral metabolism,” in
Endocrinology and Metabolism,P .F e l i g ,J .D .B a x t e r ,A .E .
Broadus, and L. A. Frohman, Eds., pp. 1317–1453, McGraw-
Hill, New York, NY, USA, 2nd edition, 1987.
[132] C. K. Welt, J. L. Chan, J. Bullen, et al., “Recombinant human
leptin in women with hypothalamic amenorrhea,” The New
England Journal of Medicine, vol. 351, no. 10, pp. 987–997,
2004.
[133] B. A. Kaufman, M. P. Warren, J. E. Dominguez, J. Wang, S.
B. Heymsﬁeld, and R. N. Pierson, “Bone density and amen-
orrhea in ballet dancers are related to a decreased resting
metabolicrateandlowerleptinlevels,” TheJournalofClinical
Endocrinology & Metabolism, vol. 87, no. 6, pp. 2777–2783,
2002.
[134] S. A. Lear, R. P. Pauly, and C. L. Birmingham, “Body fat,
caloric intake, and plasma leptin levels in women with
anorexia nervosa,” International Journal of Eating Disorders,
vol. 26, no. 3, pp. 283–288, 1999.
[135] J. M. Turner, M. K. Bulsara, B. M. McDermott, G. C. Byrne,
R. L. Prince, and D. A. Forbes, “Predictors of low bone den-
sity in young adolescent females with anorexia nervosa and
other dieting disorders,” International Journal of Eating Dis-
orders, vol. 30, no. 3, pp. 245–251, 2001.
[136] K. E. Ensrud, R. L. Fullman, E. Barrett-Connor, et al., “Vol-
untaryweightreductioninoldermenincreaseshipboneloss:
t h eo s t e o p o r o t i cf r a c t u r e si nm e ns t u d y , ”Journal of Clinical
Endocrinology & Metabolism, vol. 90, no. 4, pp. 1998–2004,
2005.
[137] J. M. Johnson, J. W. Maher, I. Samuel, D. Heitshusen, C. Do-
herty,andR.W.Downs,“Eﬀectsofgastricbypassprocedures
onbonemineraldensity,calcium,parathyroidhormone,and
vitamin D,” Journal of Gastrointestinal Surgery,v o l .9 ,n o .8 ,
pp. 1106–1110, 2005.
[138] M. Rosenbaum, R. Goldsmith, D. Bloomﬁeld, et al., “Low-
dose leptin reverses skeletal muscle, autonomic, and neu-
roendocrine adaptations to maintenance of reduced weight,”
The Journal of Clinical Investigation, vol. 115, no. 12, pp.
3579–3586, 2005.
[139] S. Bogdanovich, K. J. Perkins, T. O. Krag, L. A. Whittemore,
a n dT .S .K h u r a n a ,“ M y o s t a t i np r o p e p t i d e - m e d i a t e da m e l i o -
ration of dystrophic pathophysiology,” The FASEB Journal,
vol. 19, no. 6, pp. 543–549, 2005.
[140] S. J. Lee, L. A. Reed, M. V. Davies, et al., “Regulation of mus-
cle growth by multiple ligands signaling through activin type
II receptors,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 102, no. 50, pp. 18117–
18122, 2005.
[141] R. Du, Y. F. Chen, X. R. An, et al., “Cloning and sequence
analysis of myostatin promoter in sheep,” DNA Sequence—
Journal of DNA Sequencing and Mapping,v o l .1 6 ,n o .6 ,p p .
412–417, 2005.
[142] H.Gilson,O.Schakman,L.Combaret,etal.,“Myostatingene
deletion prevents glucocorticoid-induced muscle atrophy,”
Endocrinology, vol. 148, no. 1, pp. 452–460, 2007.
[143] E. Ayroldi, G. Migliorati, S. Bruscoli, et al., “Modulation of
T-cell activation by the glucocorticoid-induced leucine zip-
per factor via inhibition of nuclear factor κB,” Blood, vol. 98,
no. 3, pp. 743–753, 2001.